The NHS is starting the world’s first vaccine programme to prevent gonorrhoea, using the 4CMenB meningitis vaccine in high‑risk groups from August 2025.
Long-term COVID-19 effects have been decreased from anywhere between 50 and 80% for those who have been vaccinated when compared to unvaccinated people.
Using almost $30 million in funding, an all-in-one vaccine is being developed to bring new protection against a range of new and existing coronavirus variants.
The most recent omicron subvariants have caused new infection spikes across the United States, as researchers find they are better at eluding vaccines.
A Phase 1 clinical trial of a universal flu vaccine has started inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Maryland.
Gaspary Mwanyika from the SACIDS Foundation for One Health, Sokoine University of Agriculture, Tanzania details the importance of genomic characterisation in the control of dengue.
Peter Bretscher, from the University of Saskatchewan looks at whether mouse models of cutaneous leishmaniasis are pertinent for vaccination against and treatment of AIDS, infectious diseases, and cancer.
This ‘unusual’ monkeypox outbreak has been found to be larger and more widespread than previous outbreaks outside of Africa, and health experts propose better preparation.
